Search Results - David Shames

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials by Joanna Roder, Heinrich Roder, Senait Asmellash, Minu Srivastava, Wei Zou, Mark McCleland, David Shames, Laura Maguire, Steven Rightmyer, Patrick Norman, Lelia Net, Thomas Campbell, Robert Georgantas

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the pha... by Eugene Kim, Federico Cappuzzo, Martin Reck, Wei Zou, Mark A Socinski, Mark McCleland, Makoto Nishio, Stefanie Morris, David Shames, Meghna Das Thakur, Tony SK Mok, Howard Jack West, Robert M Jotte, Geetha Shankar

Get full text

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer by Xueping Qu, Habib Hamidi, Radia M. Johnson, Ethan S. Sokol, Eva Lin, Cathy Eng, Tae Won Kim, Johanna Bendell, Smruthy Sivakumar, Benjamin Kaplan, Felipe de Sousa e Melo, Andrew Mancini, Matthew Wongchenko, Yi Shi, David Shames, Yibing Yan, Fortunato Ciardiello, Carlos Bais

Get full text

Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents by Anne C. Chiang, MD, PhD, Russell W. Madison, MS, Zoe June Assaf, PhD, Alexander Fine, PhD, Yi Cao, PhD, Ole Gjoerup, PhD, Yanmei Huang, PhD, Dexter X. Jin, PhD, Jason Hughes, PhD, Vladan Antic, MD, PhD, Amanda Young, PhD, David Fabrizio, MS, David Shames, PhD, Sophia Maund, PhD, Alexia Exarchos, MPH, Shailendra Lakhanpal, MD, Richard Zuniga, MD, Lincoln W. Pasquina, PhD, Katja Schulze, PhD

Get full text